U.S. and Israel to align drug approvals—without explicit privacy safeguards
H.R. 661 — MIRACLE Medical Technology Act of 2025 · Filed by Vern Buchanan (R-FL) · 3 cosponsors · Introduced Jan 23, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a formal U.S.-Israel partnership program to jointly develop and commercialize medical devices, pharmaceuticals, biologics, and digital health technologies. The Secretary of Health and Human Services will coordinate with Israeli counterparts to align regulatory standards, share health data for research, establish joint manufacturing facilities, and accelerate product approvals—with $8 million annually authorized through 2030.
Why we flagged it
The bill's core function is to establish a formal government-to-government framework for aligning U.S. and Israeli regulatory standards, facilitating technology transfer, and enabling joint commercialization of medical products—not a routine health initiative. The emphasis on 'regulatory harmonization,' 'intellectual property protection,' and 'commercialization frameworks' reveals a private-sector-oriented partnership structure.
What the text implies
- Health data sharing with Israel's Ministry of Health is authorized without explicit congressional oversight of privacy safeguards, data residency, or cybersecurity standards beyond vague language about 'encouraging' them.
- Regulatory harmonization with Israeli authorities may lower FDA approval standards for biologics and devices if mutual recognition agreements are pursued, potentially accelerating products to market without full U.S. safety review.
- The bill authorizes joint manufacturing facilities in the U.S. but does not require that publicly-funded research or manufacturing capacity benefit U.S. patients through price controls or public-health prioritization.
- Intellectual property protections and regulatory data protection for biologics may extend market exclusivity periods, raising drug costs for U.S. consumers while benefiting Israeli and U.S. pharmaceutical companies.
- The 'special focus on early-stage clinical trials' and 'accelerated development' language suggests expedited pathways that may reduce post-market surveillance or long-term safety monitoring.
Who it affects
Citizens may benefit from faster innovation, lower drug costs through manufacturing efficiency, and improved health technologies. However, the bill prioritizes regulatory harmonization and data-sharing with a foreign government without explicit safeguards for patient privacy, drug pricing oversight, or ensuring public benefit from publicly-funded research. The mechanism favors private-sector commercialization over public health outcomes.
Who stands to gain
- pharmaceutical companies (U.S. and Israeli)
- medical device manufacturers
- biologics/biotech firms
- health IT and digital health vendors
- contract research organizations
- private equity in healthcare
Named in the bill
Secretary of Health and Human Services, Secretary of Department of Commerce, Centers for Medicare & Medicaid Services, Food and Drug Administration, Ministry of Health of Israel, Project Orbis (oncology regulatory pathway), U.S.-Israel Health Care Collaboration Center
Where it stands
3 cosponsors: 2 Democrats, 1 Republicans.
- Jan 23, 2025 — Introduced · Congress.gov: “Introduced in House”
- Jan 23, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
2 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $18,080,000 in lobbying spend. A filing names 79 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 41% of bills with at least one filing.
Vern Buchanan, the sponsor, reported $544,700 in PAC receipts in the 2026 cycle.
- Chamber of Commerce of the U.S.A. — $17,960,000 on 1 filing
- Hadassah, the Women's Zionist Organization of America, Inc. — $120,000 on 2 filings
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the full bill text on Jun 8, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“U.S. and Israel to align drug approvals—without explicit privacy safeguards” QuorumCivic. https://share.quorumcivic.app/bill/119/hr661 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.